Tripterine treatment improves endothelial progenitor cell function via integrin-linked kinase

Area of Science:

• Vascular Biology
• Cellular Biology
• Pharmacology

Background:

• Atherosclerosis is linked to impaired endothelial progenitor cell (EPC) function.
• Tripterine, from Tripterygium wilfordii, possesses anti-inflammatory properties.
• The study investigates tripterine's potential to enhance EPC function for therapeutic applications.

Purpose of the Study:

• To determine if tripterine can improve endothelial progenitor cell (EPC) function.
• To elucidate the molecular mechanisms underlying tripterine's effects on EPCs.
• To evaluate tripterine's efficacy in an atherosclerosis mouse model.

Main Methods:

• EPCs were preconditioned with tripterine and exposed to oxidized low-density lipoprotein (ox-LDL).
• Molecular analysis focused on the integrin-linked kinase (ILK)/Akt signaling pathway.
• Atherosclerotic mice received tripterine-treated EPCs to assess in vivo effects.

Main Results:

• Tripterine improved EPC proliferation, migration, adhesion, and tube formation while reducing apoptosis.
• Tripterine restored ox-LDL-downregulated ILK levels, implicating the ILK/Akt pathway.
• In vivo, tripterine reduced aortic lesions and plaque deposition in atherosclerotic mice.

Conclusions:

• Tripterine enhances EPC function, offering a potential therapeutic strategy for atherosclerosis.
• The ILK signaling pathway is a key mechanism through which tripterine exerts its beneficial effects.
• Tripterine improves vascular function by boosting EPC performance in an atherosclerotic context.